BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shen F, Zheng RD, Sun XQ, Ding WJ, Wang XY, Fan JG. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. Hepatobiliary Pancreat Dis Int. 2017;16:375-381. [PMID: 28823367 DOI: 10.1016/s1499-3872(17)60019-5] [Cited by in Crossref: 144] [Cited by in F6Publishing: 93] [Article Influence: 36.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu G, Chong HX, Chung FY, Li Y, Liong MT. Lactobacillus plantarum DR7 Modulated Bowel Movement and Gut Microbiota Associated with Dopamine and Serotonin Pathways in Stressed Adults. Int J Mol Sci 2020;21:E4608. [PMID: 32610495 DOI: 10.3390/ijms21134608] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
2 Xu H, Huang W, Hou Q, Kwok LY, Laga W, Wang Y, Ma H, Sun Z, Zhang H. Oral Administration of Compound Probiotics Improved Canine Feed Intake, Weight Gain, Immunity and Intestinal Microbiota. Front Immunol 2019;10:666. [PMID: 31001271 DOI: 10.3389/fimmu.2019.00666] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 8.3] [Reference Citation Analysis]
3 Lou J, Jiang Y, Rao B, Li A, Ding S, Yan H, Zhou H, Liu Z, Shi Q, Cui G, Yu Z, Ren Z. Fecal Microbiomes Distinguish Patients With Autoimmune Hepatitis From Healthy Individuals. Front Cell Infect Microbiol 2020;10:342. [PMID: 32850468 DOI: 10.3389/fcimb.2020.00342] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Lensu S, Pariyani R, Mäkinen E, Yang B, Saleem W, Munukka E, Lehti M, Driuchina A, Lindén J, Tiirola M, Lahti L, Pekkala S. Prebiotic Xylo-Oligosaccharides Ameliorate High-Fat-Diet-Induced Hepatic Steatosis in Rats. Nutrients 2020;12:E3225. [PMID: 33105554 DOI: 10.3390/nu12113225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
5 Han H, Jiang Y, Wang M, Melaku M, Liu L, Zhao Y, Everaert N, Yi B, Zhang H. Intestinal dysbiosis in nonalcoholic fatty liver disease (NAFLD): focusing on the gut-liver axis. Crit Rev Food Sci Nutr 2021;:1-18. [PMID: 34404276 DOI: 10.1080/10408398.2021.1966738] [Reference Citation Analysis]
6 Zhou J, Viles WD, Lu B, Li Z, Madan JC, Karagas MR, Gui J, Hoen AG. Identification of microbial interaction network: zero-inflated latent Ising model based approach. BioData Min 2020;13:16. [PMID: 33042226 DOI: 10.1186/s13040-020-00226-7] [Reference Citation Analysis]
7 Tsai MC, Liu YY, Lin CC, Wang CC, Wu YJ, Yong CC, Chen KD, Chuah SK, Yao CC, Huang PY, Chen CH, Hu TH, Chen CL. Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan. Nutrients 2020;12:E820. [PMID: 32204538 DOI: 10.3390/nu12030820] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
8 Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W, Cholankeril G, Kim D, Ahmed A. The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD. Diseases 2019;7:E27. [PMID: 30823570 DOI: 10.3390/diseases7010027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
9 Khan A, Ding Z, Ishaq M, Bacha AS, Khan I, Hanif A, Li W, Guo X. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates. Int J Biol Sci 2021;17:818-33. [PMID: 33767591 DOI: 10.7150/ijbs.56214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Fukui H. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far? Diseases. 2019;7. [PMID: 31726747 DOI: 10.3390/diseases7040058] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 10.3] [Reference Citation Analysis]
11 Yin R, Liu S, Jiang X, Zhang X, Wei F, Hu J. The Qingchangligan Formula Alleviates Acute Liver Failure by Regulating Galactose Metabolism and Gut Microbiota. Front Cell Infect Microbiol 2022;11:771483. [DOI: 10.3389/fcimb.2021.771483] [Reference Citation Analysis]
12 Li H, Wang Q, Chen P, Zhou C, Zhang X, Chen L. Ursodeoxycholic Acid Treatment Restores Gut Microbiota and Alleviates Liver Inflammation in Non-Alcoholic Steatohepatitic Mouse Model. Front Pharmacol 2021;12:788558. [PMID: 34938193 DOI: 10.3389/fphar.2021.788558] [Reference Citation Analysis]
13 Kessoku T, Kobayashi T, Imajo K, Tanaka K, Yamamoto A, Takahashi K, Kasai Y, Ozaki A, Iwaki M, Nogami A, Honda Y, Ogawa Y, Kato S, Higurashi T, Hosono K, Yoneda M, Okamoto T, Usuda H, Wada K, Kobayashi N, Saito S, Nakajima A. Endotoxins and Non-Alcoholic Fatty Liver Disease. Front Endocrinol (Lausanne) 2021;12:770986. [PMID: 34777261 DOI: 10.3389/fendo.2021.770986] [Reference Citation Analysis]
14 Zhang N, Gou Y, Liang S, Chen N, Liu Y, He Q, Zhang J. Dysbiosis of Gut Microbiota Promotes Hepatocellular Carcinoma Progression by Regulating the Immune Response. J Immunol Res 2021;2021:4973589. [PMID: 34722779 DOI: 10.1155/2021/4973589] [Reference Citation Analysis]
15 Sharma SP, Suk KT, Kim DJ. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. World J Gastroenterol 2021; 27(37): 6161-6179 [PMID: 34712025 DOI: 10.3748/wjg.v27.i37.6161] [Reference Citation Analysis]
16 Sharpton SR, Ajmera V, Loomba R. Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. Clin Gastroenterol Hepatol 2019;17:296-306. [PMID: 30196156 DOI: 10.1016/j.cgh.2018.08.065] [Cited by in Crossref: 62] [Cited by in F6Publishing: 51] [Article Influence: 15.5] [Reference Citation Analysis]
17 Liu C, Du MX, Abuduaini R, Yu HY, Li DH, Wang YJ, Zhou N, Jiang MZ, Niu PX, Han SS, Chen HH, Shi WY, Wu L, Xin YH, Ma J, Zhou Y, Jiang CY, Liu HW, Liu SJ. Enlightening the taxonomy darkness of human gut microbiomes with a cultured biobank. Microbiome 2021;9:119. [PMID: 34020714 DOI: 10.1186/s40168-021-01064-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Nishikawa H, Enomoto H, Nishiguchi S, Iijima H. Liver Cirrhosis and Sarcopenia from the Viewpoint of Dysbiosis. Int J Mol Sci. 2020;21:5254. [PMID: 32722100 DOI: 10.3390/ijms21155254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
19 Sarkar S, Kimono D, Albadrani M, Seth RK, Busbee P, Alghetaa H, Porter DE, Scott GI, Brooks B, Nagarkatti M, Nagarkatti P, Chatterjee S. Environmental microcystin targets the microbiome and increases the risk of intestinal inflammatory pathology via NOX2 in underlying murine model of Nonalcoholic Fatty Liver Disease. Sci Rep 2019;9:8742. [PMID: 31217465 DOI: 10.1038/s41598-019-45009-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
20 Hrncir T, Hrncirova L, Kverka M, Hromadka R, Machova V, Trckova E, Kostovcikova K, Kralickova P, Krejsek J, Tlaskalova-Hogenova H. Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions. Microorganisms 2021;9:957. [PMID: 33946843 DOI: 10.3390/microorganisms9050957] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
21 Sun J, Zhao F, Lin B, Feng J, Wu X, Liu Y, Zhao L, Zhu B, Wei Y. Gut Microbiota Participates in Antithyroid Drug Induced Liver Injury Through the Lipopolysaccharide Related Signaling Pathway. Front Pharmacol 2020;11:598170. [PMID: 33390986 DOI: 10.3389/fphar.2020.598170] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, Mileti E, Galbiati M, Invernizzi P, Adorini L, Penna G, Rescigno M. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol. 2019;71:1216-1228. [PMID: 31419514 DOI: 10.1016/j.jhep.2019.08.005] [Cited by in Crossref: 103] [Cited by in F6Publishing: 107] [Article Influence: 34.3] [Reference Citation Analysis]
23 Pedersen KB, Pulliam CF, Patel A, Del Piero F, Watanabe TTN, Wankhade UD, Shankar K, Hicks C, Ronis MJ. Liver tumorigenesis is promoted by a high saturated fat diet specifically in male mice and is associated with hepatic expression of the proto-oncogene Agap2 and enrichment of the intestinal microbiome with Coprococcus. Carcinogenesis 2019;40:349-59. [PMID: 30325408 DOI: 10.1093/carcin/bgy141] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
24 Kang K, Sun Y, Pan D, Sang LX, Sun MJ, Li YL, Chang B. Distinctive gut microbial dysbiosis between chronic alcoholic fatty liver disease and metabolic-associated fatty liver disease in mice. Exp Ther Med 2021;21:418. [PMID: 33777186 DOI: 10.3892/etm.2021.9862] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
25 Yu Q, Wu L, Ji J, Feng J, Dai W, Li J, Wu J, Guo C. Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma. J Hepatocell Carcinoma 2020;7:271-88. [PMID: 33150145 DOI: 10.2147/JHC.S277870] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
26 Wu W, Liu L, Zhu H, Sun Y, Wu Y, Liao H, Gui Y, Li L, Liu L, Sun F, Lin H. Butyrolactone-I, an efficient α-glucosidase inhibitor, improves type 2 diabetes with potent TNF-α-lowering properties through modulating gut microbiota in db/db mice. FASEB J 2019;33:12616-29. [PMID: 31450982 DOI: 10.1096/fj.201901061R] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
27 Wahlang B, Alexander NC 2nd, Li X, Rouchka EC, Kirpich IA, Cave MC. Polychlorinated biphenyls altered gut microbiome in CAR and PXR knockout mice exhibiting toxicant-associated steatohepatitis. Toxicol Rep 2021;8:536-47. [PMID: 33777700 DOI: 10.1016/j.toxrep.2021.03.010] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Carbajo-Pescador S, Porras D, García-Mediavilla MV, Martínez-Flórez S, Juarez-Fernández M, Cuevas MJ, Mauriz JL, González-Gallego J, Nistal E, Sánchez-Campos S. Beneficial effects of exercise on gut microbiota functionality and barrier integrity, and gut-liver crosstalk in an in vivo model of early obesity and non-alcoholic fatty liver disease. Dis Model Mech 2019;12:dmm039206. [PMID: 30971408 DOI: 10.1242/dmm.039206] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
29 Li Y, Hou JJ, Wang X, Su S, Wang YM, Zhang J. New progress in research of intestinal microbiota in fatty liver disease. Shijie Huaren Xiaohua Zazhi 2021; 29(23): 1355-1361 [DOI: 10.11569/wcjd.v29.i23.1355] [Reference Citation Analysis]
30 Ronis MJ, Mercer KE, Shankar K, Pulliam C, Pedersen K, Ingelman-Sundberg M, Friso S, Samuelson D, Del Valle L, Taylor C, Welsh DA. Potential role of gut microbiota, the proto-oncogene PIKE (Agap2) and cytochrome P450 CYP2W1 in promotion of liver cancer by alcoholic and nonalcoholic fatty liver disease and protection by dietary soy protein. Chem Biol Interact 2020;325:109131. [PMID: 32417163 DOI: 10.1016/j.cbi.2020.109131] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Han S, Guan Y, Dou H, Yang H, Yao M, Ge J, Feng L. Comparison of the fecal microbiota of two free-ranging Chinese subspecies of the leopard (Panthera pardus) using high-throughput sequencing. PeerJ 2019;7:e6684. [PMID: 30944781 DOI: 10.7717/peerj.6684] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
32 He LH, Yao DH, Wang LY, Zhang L, Bai XL. Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. Front Microbiol 2021;12:761836. [PMID: 34795655 DOI: 10.3389/fmicb.2021.761836] [Reference Citation Analysis]
33 Andrade FO, Liu F, Zhang X, Rosim MP, Dani C, Cruz I, Wang TTY, Helferich W, Li RW, Hilakivi-Clarke L. Genistein Reduces the Risk of Local Mammary Cancer Recurrence and Ameliorates Alterations in the Gut Microbiota in the Offspring of Obese Dams. Nutrients 2021;13:201. [PMID: 33440675 DOI: 10.3390/nu13010201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
34 Ren Z, Li A, Jiang J, Zhou L, Yu Z, Lu H, Xie H, Chen X, Shao L, Zhang R, Xu S, Zhang H, Cui G, Sun R, Wen H, Lerut JP, Kan Q, Li L, Zheng S. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut. 2019;68:1014-1023. [PMID: 30045880 DOI: 10.1136/gutjnl-2017-315084] [Cited by in Crossref: 156] [Cited by in F6Publishing: 154] [Article Influence: 39.0] [Reference Citation Analysis]
35 Castillo-Castro C, Martagón-Rosado AJ, Ortiz-Lopez R, Garrido-Treviño LF, Villegas-Albo M, Bosques-Padilla FJ. Promising diagnostic biomarkers of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: From clinical proteomics to microbiome. World J Hepatol 2021; 13(11): 1494-1511 [PMID: 34904026 DOI: 10.4254/wjh.v13.i11.1494] [Reference Citation Analysis]
36 Hullar MAJ, Jenkins IC, Randolph TW, Curtis KR, Monroe KR, Ernst T, Shepherd JA, Stram DO, Cheng I, Kristal BS, Wilkens LR, Franke A, Le Marchand L, Lim U, Lampe JW. Associations of the gut microbiome with hepatic adiposity in the Multiethnic Cohort Adiposity Phenotype Study. Gut Microbes 2021;13:1965463. [PMID: 34491886 DOI: 10.1080/19490976.2021.1965463] [Reference Citation Analysis]
37 Gao Q, Han ZY, Tian DF, Liu GL, Wang ZY, Lin JF, Chang Z, Zhang DD, Xie YZ, Sun YK, Yao XW, Ma DY. Xinglou Chengqi Decoction improves neurological function in experimental stroke mice as evidenced by gut microbiota analysis and network pharmacology. Chin J Nat Med 2021;19:881-99. [PMID: 34961587 DOI: 10.1016/S1875-5364(21)60079-1] [Reference Citation Analysis]
38 Shi J, Yang Y, Xu W, Cai H, Wu J, Long J, Cai Q, Zheng W, Flynn CR, Shu XO, Yu D. Sex-Specific Associations between Gut Microbiome and Non-Alcoholic Fatty Liver Disease among Urban Chinese Adults. Microorganisms 2021;9:2118. [PMID: 34683439 DOI: 10.3390/microorganisms9102118] [Reference Citation Analysis]
39 Morrissette M, Pitt N, González A, Strandwitz P, Caboni M, Rebman AW, Knight R, D'Onofrio A, Aucott JN, Soloski MJ, Lewis K. A Distinct Microbiome Signature in Posttreatment Lyme Disease Patients. mBio 2020;11:e02310-20. [PMID: 32994327 DOI: 10.1128/mBio.02310-20] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
40 Liu X, Zheng H, Lu R, Huang H, Zhu H, Yin C, Mo Y, Wu J, Liu X, Deng M, Li D, Cheng B, Wu F, Liang Y, Guo H, Song H, Su Z. Intervening Effects of Total Alkaloids of Corydalis saxicola Bunting on Rats With Antibiotic-Induced Gut Microbiota Dysbiosis Based on 16S rRNA Gene Sequencing and Untargeted Metabolomics Analyses. Front Microbiol 2019;10:1151. [PMID: 31214133 DOI: 10.3389/fmicb.2019.01151] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
41 Jennison E, Byrne CD. The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. Clin Mol Hepatol 2021;27:22-43. [PMID: 33291863 DOI: 10.3350/cmh.2020.0129] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
42 Sui G, Jia L, Quan D, Zhao N, Yang G. Activation of the gut microbiota-kynurenine-liver axis contributes to the development of nonalcoholic hepatic steatosis in nondiabetic adults. Aging (Albany NY) 2021;13:21309-24. [PMID: 34473644 DOI: 10.18632/aging.203460] [Reference Citation Analysis]
43 Jadhav K, Cohen TS. Can You Trust Your Gut? Front Endocrinol (Lausanne). 2020;11:592157. [PMID: 33193105 DOI: 10.3389/fendo.2020.592157] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
44 Chen Y, Wang Q, Gao W, Ma B, Xue D, Hao C. Changes and Correlations of the Intestinal Flora and Liver Metabolite Profiles in Mice With Gallstones. Front Physiol 2021;12:716654. [PMID: 34489732 DOI: 10.3389/fphys.2021.716654] [Reference Citation Analysis]
45 Jiang JW, Ren ZG, Lu HF, Zhang H, Li A, Cui GY, Jia JJ, Xie HY, Chen XH, He Y, Jiang L, Li LJ. Optimal immunosuppressor induces stable gut microbiota after liver transplantation. World J Gastroenterol 2018; 24(34): 3871-3883 [PMID: 30228781 DOI: 10.3748/wjg.v24.i34.3871] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
46 Li F, Ye J, Shao C, Zhong B. Compositional alterations of gut microbiota in nonalcoholic fatty liver disease patients: a systematic review and Meta-analysis. Lipids Health Dis 2021;20:22. [PMID: 33637088 DOI: 10.1186/s12944-021-01440-w] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
47 Dong TS, Jacobs JP. Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver? Exp Biol Med (Maywood) 2019;244:408-18. [PMID: 30871368 DOI: 10.1177/1535370219836739] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
48 Aron-wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom AG, Verheij J, Nieuwdorp M, Clément K. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020;17:279-97. [DOI: 10.1038/s41575-020-0269-9] [Cited by in Crossref: 103] [Cited by in F6Publishing: 103] [Article Influence: 51.5] [Reference Citation Analysis]
49 Zhou D, Fan JG. Microbial metabolites in non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(17): 2019-2028 [PMID: 31114130 DOI: 10.3748/wjg.v25.i17.2019] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 23] [Article Influence: 9.3] [Reference Citation Analysis]
50 Miao ZH, Zhou WX, Cheng RY, Liang HJ, Jiang FL, Shen X, Lu JH, Li M, He F. Dysbiosis of intestinal microbiota in early life aggravates high-fat diet induced dysmetabolism in adult mice. BMC Microbiol 2021;21:209. [PMID: 34238228 DOI: 10.1186/s12866-021-02263-6] [Reference Citation Analysis]
51 Ni J, Huang R, Zhou H, Xu X, Li Y, Cao P, Zhong K, Ge M, Chen X, Hou B, Yu M, Peng B, Li Q, Zhang P, Gao Y. Analysis of the Relationship Between the Degree of Dysbiosis in Gut Microbiota and Prognosis at Different Stages of Primary Hepatocellular Carcinoma. Front Microbiol 2019;10:1458. [PMID: 31293562 DOI: 10.3389/fmicb.2019.01458] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
52 Baumann A, Nier A, Hernández-Arriaga A, Brandt A, Lorenzo Pisarello MJ, Jin CJ, Pilar E, Camarinha-Silva A, Schattenberg JM, Bergheim I. Toll-like receptor 1 as a possible target in non-alcoholic fatty liver disease. Sci Rep 2021;11:17815. [PMID: 34497333 DOI: 10.1038/s41598-021-97346-9] [Reference Citation Analysis]
53 Chiang JYL, Ferrell JM. Bile acid receptors FXR and TGR5 signaling in fatty liver diseases and therapy. Am J Physiol Gastrointest Liver Physiol. 2020;318:G554-G573. [PMID: 31984784 DOI: 10.1152/ajpgi.00223.2019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 14.0] [Reference Citation Analysis]
54 Martín-Mateos R, Albillos A. The Role of the Gut-Liver Axis in Metabolic Dysfunction-Associated Fatty Liver Disease. Front Immunol 2021;12:660179. [PMID: 33936094 DOI: 10.3389/fimmu.2021.660179] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
55 Zhao ZH, Xin FZ, Zhou D, Xue YQ, Liu XL, Yang RX, Pan Q, Fan JG. Trimethylamine N-oxide attenuates high-fat high-cholesterol diet-induced steatohepatitis by reducing hepatic cholesterol overload in rats. World J Gastroenterol 2019; 25(20): 2450-2462 [PMID: 31171889 DOI: 10.3748/wjg.v25.i20.2450] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
56 Yang XF, Lu M, You L, Gen H, Yuan L, Tian T, Li CY, Xu K, Hou J, Lei M. Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology. Chin Med 2021;16:62. [PMID: 34315516 DOI: 10.1186/s13020-021-00470-x] [Reference Citation Analysis]
57 Temraz S, Nassar F, Kreidieh F, Mukherji D, Shamseddine A, Nasr R. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome. Int J Mol Sci 2021;22:7800. [PMID: 34360566 DOI: 10.3390/ijms22157800] [Reference Citation Analysis]
58 Hoozemans J, de Brauw M, Nieuwdorp M, Gerdes V. Gut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review. Metabolites 2021;11:353. [PMID: 34072995 DOI: 10.3390/metabo11060353] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
59 Wei L, Li Y, Tang W, Sun Q, Chen L, Wang X, Liu Q, Yu S, Yu S, Liu C, Ma X. Chronic Unpredictable Mild Stress in Rats Induces Colonic Inflammation. Front Physiol 2019;10:1228. [PMID: 31616319 DOI: 10.3389/fphys.2019.01228] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
60 Chen Q, Wang Y, Jiao F, Shi C, Pei M, Wang L, Gong Z. Betaine inhibits Toll-like receptor 4 responses and restores intestinal microbiota in acute liver failure mice. Sci Rep 2020;10:21850. [PMID: 33318565 DOI: 10.1038/s41598-020-78935-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
61 Li Y, Zhang B, Zhou Y, Wang D, Liu X, Li L, Wang T, Zhang Y, Jiang M, Tang H, Amsel LV, Fan F, Hoven CW. Gut Microbiota Changes and Their Relationship with Inflammation in Patients with Acute and Chronic Insomnia. Nat Sci Sleep 2020;12:895-905. [PMID: 33177907 DOI: 10.2147/NSS.S271927] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
62 Li YL, Xiao NQ, Tan ZJ. Intestinal microflora in metabolic diseases. Shijie Huaren Xiaohua Zazhi 2020; 28(23): 1192-1199 [DOI: 10.11569/wcjd.v28.i23.1192] [Reference Citation Analysis]
63 Zhou J, Tripathi M, Sinha RA, Singh BK, Yen PM. Gut microbiota and their metabolites in the progression of non-alcoholic fatty liver disease. Hepatoma Res 2021;7:11. [PMID: 33490737 DOI: 10.20517/2394-5079.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
64 Wang Q, Lv L, Jiang H, Wang K, Yan R, Li Y, Ye J, Wu J, Wang Q, Bian X, Yang L, Jiang X, Xie J, Lu Y, Shen J, Li L. Lactobacillus helveticus R0052 alleviates liver injury by modulating gut microbiome and metabolome in D-galactosamine-treated rats. Appl Microbiol Biotechnol 2019;103:9673-86. [PMID: 31713675 DOI: 10.1007/s00253-019-10211-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
65 Huang H, Ren Z, Gao X, Hu X, Zhou Y, Jiang J, Lu H, Yin S, Ji J, Zhou L, Zheng S. Integrated analysis of microbiome and host transcriptome reveals correlations between gut microbiota and clinical outcomes in HBV-related hepatocellular carcinoma. Genome Med. 2020;12:102. [PMID: 33225985 DOI: 10.1186/s13073-020-00796-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
66 Jiang Y, Chowdhury S, Xu BH, Meybodi MA, Damiris K, Devalaraju S, Pyrsopoulos N. Nonalcoholic fatty liver disease is associated with worse intestinal complications in patients hospitalized for Clostridioides difficile infection. World J Hepatol 2021; 13(11): 1777-1790 [PMID: 34904045 DOI: 10.4254/wjh.v13.i11.1777] [Reference Citation Analysis]
67 Vijay A, Valdes AM. Role of the gut microbiome in chronic diseases: a narrative review. Eur J Clin Nutr 2021. [PMID: 34584224 DOI: 10.1038/s41430-021-00991-6] [Reference Citation Analysis]
68 Zhang WD, Yao WL, He WH, Li JF, Wu XP, Chen ZH, Liu L, Wang WH. Bacterial community analysis on the different mucosal immune inductive sites of gastrointestinal tract in Bactrian camels. PLoS One 2020;15:e0239987. [PMID: 33031424 DOI: 10.1371/journal.pone.0239987] [Reference Citation Analysis]
69 Ahmed BA, Ong FJ, Barra NG, Blondin DP, Gunn E, Oreskovich SM, Szamosi JC, Syed SA, Hutchings EK, Konyer NB, Singh NP, Yabut JM, Desjardins EM, Anhê FF, Foley KP, Holloway AC, Noseworthy MD, Haman F, Carpentier AC, Surette MG, Schertzer JD, Punthakee Z, Steinberg GR, Morrison KM. Lower brown adipose tissue activity is associated with non-alcoholic fatty liver disease but not changes in the gut microbiota. Cell Rep Med 2021;2:100397. [PMID: 34622234 DOI: 10.1016/j.xcrm.2021.100397] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
70 Wu H, Li Y, Meng Q, Zhou Z. Effect of High Sulfur Diet on Rumen Fermentation, Microflora, and Epithelial Barrier Function in Steers. Animals (Basel) 2021;11:2545. [PMID: 34573510 DOI: 10.3390/ani11092545] [Reference Citation Analysis]
71 Wang T, Guo XK, Xu H. Disentangling the Progression of Non-alcoholic Fatty Liver Disease in the Human Gut Microbiota. Front Microbiol 2021;12:728823. [PMID: 34721326 DOI: 10.3389/fmicb.2021.728823] [Reference Citation Analysis]
72 Lin H, Meng L, Sun Z, Sun S, Huang X, Lin N, Zhang J, Lu W, Yang Q, Chi J, Guo H. Yellow Wine Polyphenolic Compound Protects Against Doxorubicin-Induced Cardiotoxicity by Modulating the Composition and Metabolic Function of the Gut Microbiota. Circ Heart Fail 2021;14:e008220. [PMID: 34665676 DOI: 10.1161/CIRCHEARTFAILURE.120.008220] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Xin FZ, Zhao ZH, Liu XL, Pan Q, Wang ZX, Zeng L, Zhang QR, Ye L, Wang MY, Zhang RN, Gong ZZ, Huang LJ, Sun C, Shen F, Jiang L, Fan JG. Escherichia fergusonii Promotes Nonobese Nonalcoholic Fatty Liver Disease by Interfering With Host Hepatic Lipid Metabolism Through Its Own msRNA 23487. Cell Mol Gastroenterol Hepatol 2021:S2352-345X(21)00253-8. [PMID: 34902629 DOI: 10.1016/j.jcmgh.2021.12.003] [Reference Citation Analysis]
74 Krawczyk M, Maciejewska D, Ryterska K, Czerwińka-Rogowska M, Jamioł-Milc D, Skonieczna-Żydecka K, Milkiewicz P, Raszeja-Wyszomirska J, Stachowska E. Gut Permeability Might be Improved by Dietary Fiber in Individuals with Nonalcoholic Fatty Liver Disease (NAFLD) Undergoing Weight Reduction. Nutrients 2018;10:E1793. [PMID: 30453660 DOI: 10.3390/nu10111793] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 6.3] [Reference Citation Analysis]
75 Wang B, Zhou Y, Tang L, Zeng Z, Gong L, Wu Y, Li WF. Effects of Bacillus amyloliquefaciens Instead of Antibiotics on Growth Performance, Intestinal Health, and Intestinal Microbiota of Broilers. Front Vet Sci 2021;8:679368. [PMID: 34150896 DOI: 10.3389/fvets.2021.679368] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
76 Mouzaki M, Loomba R. An update on the role of the microbiome in non-alcoholic fatty liver disease pathogenesis, diagnosis, and treatment. Curr Treat Options Gastroenterol 2020;18:270-80. [PMID: 33716495 DOI: 10.1007/s11938-020-00290-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Aragonès G, González-García S, Aguilar C, Richart C, Auguet T. Gut Microbiota-Derived Mediators as Potential Markers in Nonalcoholic Fatty Liver Disease. Biomed Res Int 2019;2019:8507583. [PMID: 30719448 DOI: 10.1155/2019/8507583] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 4.7] [Reference Citation Analysis]
78 Chong CYL, Orr D, Plank LD, Vatanen T, O'Sullivan JM, Murphy R. Randomised Double-Blind Placebo-Controlled Trial of Inulin with Metronidazole in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2020;12:E937. [PMID: 32230987 DOI: 10.3390/nu12040937] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
79 Zhu B, Chan SL, Li J, Li K, Wu H, Cui K, Chen H. Non-alcoholic Steatohepatitis Pathogenesis, Diagnosis, and Treatment. Front Cardiovasc Med 2021;8:742382. [PMID: 34557535 DOI: 10.3389/fcvm.2021.742382] [Reference Citation Analysis]
80 Schwimmer JB, Johnson JS, Angeles JE, Behling C, Belt PH, Borecki I, Bross C, Durelle J, Goyal NP, Hamilton G, Holtz ML, Lavine JE, Mitreva M, Newton KP, Pan A, Simpson PM, Sirlin CB, Sodergren E, Tyagi R, Yates KP, Weinstock GM, Salzman NH. Microbiome Signatures Associated With Steatohepatitis and Moderate to Severe Fibrosis in Children With Nonalcoholic Fatty Liver Disease. Gastroenterology 2019;157:1109-22. [PMID: 31255652 DOI: 10.1053/j.gastro.2019.06.028] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 22.7] [Reference Citation Analysis]
81 Xu R, Tan C, Zhu J, Zeng X, Gao X, Wu Q, Chen Q, Wang H, Zhou H, He Y, Pan S, Yin J. Dysbiosis of the intestinal microbiota in neurocritically ill patients and the risk for death. Crit Care 2019;23:195. [PMID: 31151471 DOI: 10.1186/s13054-019-2488-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 7.0] [Reference Citation Analysis]
82 Yuan X, Zheng J, Ren L, Jiao S, Feng C, Du Y, Liu H. Glucosamine Ameliorates Symptoms of High-Fat Diet-Fed Mice by Reversing Imbalanced Gut Microbiota. Front Pharmacol 2021;12:694107. [PMID: 34149435 DOI: 10.3389/fphar.2021.694107] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Jia Q, Zhang L, Zhang J, Pei F, Zhu S, Sun Q, Duan L. Fecal Microbiota of Diarrhea-Predominant Irritable Bowel Syndrome Patients Causes Hepatic Inflammation of Germ-Free Rats and Berberine Reverses It Partially. Biomed Res Int 2019;2019:4530203. [PMID: 31073525 DOI: 10.1155/2019/4530203] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
84 López-Moreno A, Acuña I, Torres-Sánchez A, Ruiz-Moreno Á, Cerk K, Rivas A, Suárez A, Monteoliva-Sánchez M, Aguilera M. Next Generation Probiotics for Neutralizing Obesogenic Effects: Taxa Culturing Searching Strategies. Nutrients 2021;13:1617. [PMID: 34065873 DOI: 10.3390/nu13051617] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Wang N, Ma S, Fu L. Gut Microbiota Dysbiosis as One Cause of Osteoporosis by Impairing Intestinal Barrier Function. Calcif Tissue Int 2021. [PMID: 34480200 DOI: 10.1007/s00223-021-00911-7] [Reference Citation Analysis]
86 Maturana JL, Cárdenas JP. Insights on the Evolutionary Genomics of the Blautia Genus: Potential New Species and Genetic Content Among Lineages. Front Microbiol 2021;12:660920. [PMID: 33981291 DOI: 10.3389/fmicb.2021.660920] [Reference Citation Analysis]
87 Castillo V, Figueroa F, González-Pizarro K, Jopia P, Ibacache-Quiroga C. Probiotics and Prebiotics as a Strategy for Non-Alcoholic Fatty Liver Disease, a Narrative Review. Foods 2021;10:1719. [PMID: 34441497 DOI: 10.3390/foods10081719] [Reference Citation Analysis]
88 Hsiao YP, Chen HL, Tsai JN, Lin MY, Liao JW, Wei MS, Ko JL, Ou CC. Administration of Lactobacillus reuteri Combined with Clostridium butyricum Attenuates Cisplatin-Induced Renal Damage by Gut Microbiota Reconstitution, Increasing Butyric Acid Production, and Suppressing Renal Inflammation. Nutrients 2021;13:2792. [PMID: 34444952 DOI: 10.3390/nu13082792] [Reference Citation Analysis]
89 Lee BH, Chen CH, Hsu YY, Chuang PT, Shih MK, Hsu WH. Polysaccharides Obtained from Cordyceps militaris Alleviate Hyperglycemia by Regulating Gut Microbiota in Mice Fed a High-Fat/Sucrose Diet. Foods 2021;10:1870. [PMID: 34441649 DOI: 10.3390/foods10081870] [Reference Citation Analysis]
90 Wei L, Yue F, Xing L, Wu S, Shi Y, Li J, Xiang X, Lam SM, Shui G, Russell R, Zhang D. Constant Light Exposure Alters Gut Microbiota and Promotes the Progression of Steatohepatitis in High Fat Diet Rats. Front Microbiol 2020;11:1975. [PMID: 32973715 DOI: 10.3389/fmicb.2020.01975] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
91 Hatasa M, Yoshida S, Takahashi H, Tanaka K, Kubotsu Y, Ohsugi Y, Katagiri T, Iwata T, Katagiri S. Relationship between NAFLD and Periodontal Disease from the View of Clinical and Basic Research, and Immunological Response. Int J Mol Sci 2021;22:3728. [PMID: 33918456 DOI: 10.3390/ijms22073728] [Reference Citation Analysis]
92 Petrick JL, Florio AA, Koshiol J, Pfeiffer RM, Yang B, Yu K, Chen CJ, Yang HI, Lee MH, McGlynn KA. Prediagnostic concentrations of circulating bile acids and hepatocellular carcinoma risk: REVEAL-HBV and HCV studies. Int J Cancer 2020;147:2743-53. [PMID: 32406072 DOI: 10.1002/ijc.33051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
93 Fontes A, Alemany-Pagès M, Oliveira PJ, Ramalho-Santos J, Zischka H, Azul AM. Antioxidant Versus Pro-Apoptotic Effects of Mushroom-Enriched Diets on Mitochondria in Liver Disease. Int J Mol Sci 2019;20:E3987. [PMID: 31426291 DOI: 10.3390/ijms20163987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
94 Juárez-Fernández M, Porras D, Petrov P, Román-Sagüillo S, García-Mediavilla MV, Soluyanova P, Martínez-Flórez S, González-Gallego J, Nistal E, Jover R, Sánchez-Campos S. The Synbiotic Combination of Akkermansia muciniphila and Quercetin Ameliorates Early Obesity and NAFLD through Gut Microbiota Reshaping and Bile Acid Metabolism Modulation. Antioxidants (Basel) 2021;10:2001. [PMID: 34943104 DOI: 10.3390/antiox10122001] [Reference Citation Analysis]
95 Chen YH, Wu WK, Wu MS. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review. Int J Mol Sci 2020;21:E5999. [PMID: 32825440 DOI: 10.3390/ijms21175999] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
96 Filipovic B, Lukic S, Mijac D, Marjanovic-Haljilji M, Vojnovic M, Bogdanovic J, Glisic T, Filipovic N, Al Kiswani J, Djokovic A, Kapor S, Kapor S, Bukumiric Z, Starcevic A. The New Therapeutic Approaches in the Treatment of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:13219. [PMID: 34948020 DOI: 10.3390/ijms222413219] [Reference Citation Analysis]
97 Xue R, Su L, Lai S, Wang Y, Zhao D, Fan J, Chen W, Hylemon PB, Zhou H. Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease. Cells 2021;10:2806. [PMID: 34831031 DOI: 10.3390/cells10112806] [Reference Citation Analysis]
98 Si J, Lee G, You HJ, Joo SK, Lee DH, Ku BJ, Park S, Kim W, Ko G. Gut microbiome signatures distinguish type 2 diabetes mellitus from non-alcoholic fatty liver disease. Comput Struct Biotechnol J 2021;19:5920-30. [PMID: 34849196 DOI: 10.1016/j.csbj.2021.10.032] [Reference Citation Analysis]
99 Wang P, Wu L. Hydrogen sulfide and nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr 2018;7:122-4. [PMID: 29744340 DOI: 10.21037/hbsn.2018.03.03] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
100 Sharpton SR, Yong GJM, Terrault NA, Lynch SV. Gut Microbial Metabolism and Nonalcoholic Fatty Liver Disease. Hepatol Commun 2019;3:29-43. [PMID: 30619992 DOI: 10.1002/hep4.1284] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
101 Ghosh S, Yang X, Wang L, Zhang C, Zhao L. Active phase prebiotic feeding alters gut microbiota, induces weight-independent alleviation of hepatic steatosis and serum cholesterol in high-fat diet-fed mice. Comput Struct Biotechnol J 2021;19:448-58. [PMID: 33510856 DOI: 10.1016/j.csbj.2020.12.011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
102 Zhou L, Xiao X, Li M, Zhang Q, Yu M, Zheng J, Deng M. Maternal Exercise Improves High-Fat Diet-Induced Metabolic Abnormalities and Gut Microbiota Profiles in Mouse Dams and Offspring. Front Cell Infect Microbiol 2020;10:292. [PMID: 32626663 DOI: 10.3389/fcimb.2020.00292] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
103 Lanthier N, Rodriguez J, Nachit M, Hiel S, Trefois P, Neyrinck AM, Cani PD, Bindels LB, Thissen JP, Delzenne NM. Microbiota analysis and transient elastography reveal new extra-hepatic components of liver steatosis and fibrosis in obese patients. Sci Rep 2021;11:659. [PMID: 33436764 DOI: 10.1038/s41598-020-79718-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
104 Sasaki N, Katagiri S, Komazaki R, Watanabe K, Maekawa S, Shiba T, Udagawa S, Takeuchi Y, Ohtsu A, Kohda T, Tohara H, Miyasaka N, Hirota T, Tamari M, Izumi Y. Endotoxemia by Porphyromonas gingivalis Injection Aggravates Non-alcoholic Fatty Liver Disease, Disrupts Glucose/Lipid Metabolism, and Alters Gut Microbiota in Mice. Front Microbiol 2018;9:2470. [PMID: 30405551 DOI: 10.3389/fmicb.2018.02470] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
105 Mitsinikos FT, Chac D, Schillingford N, DePaolo RW. Modifying macronutrients is superior to microbiome transplantation in treating nonalcoholic fatty liver disease. Gut Microbes 2020;12:1-16. [PMID: 32816619 DOI: 10.1080/19490976.2020.1792256] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
106 Wang L, Wan YY. The role of gut microbiota in liver disease development and treatment. Liver Res 2019;3:3-18. [PMID: 32461811 DOI: 10.1016/j.livres.2019.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
107 Yang Z, Xia Q, Lu D, Yue H, Zhang J, Li Y, Zhang B, Li X, Cao M. Human mesenchymal stem cells treatment improved hepatic lesions and reversed gut microbiome disorder in non-alcoholic steatohepatitis. Aging (Albany NY) 2020;12:21660-73. [PMID: 33168782 DOI: 10.18632/aging.103962] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
108 Liao J, Liu Y, Yi J, Li Y, Li Q, Li Y, Shang P, Guo J, Hu L, Pan J, Li Y, Chang YF, Tang Z, Zhang H. Gut microbiota disturbance exaggerates battery wastewater-induced hepatotoxicity through a gut-liver axis. Sci Total Environ 2021;809:152188. [PMID: 34875328 DOI: 10.1016/j.scitotenv.2021.152188] [Reference Citation Analysis]
109 Bartolini I, Risaliti M, Tucci R, Muiesan P, Ringressi MN, Taddei A, Amedei A. Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment. World J Gastrointest Oncol 2021; 13(11): 1616-1631 [PMID: 34853639 DOI: 10.4251/wjgo.v13.i11.1616] [Reference Citation Analysis]
110 Vacca M, Celano G, Calabrese FM, Portincasa P, Gobbetti M, De Angelis M. The Controversial Role of Human Gut Lachnospiraceae. Microorganisms 2020;8:E573. [PMID: 32326636 DOI: 10.3390/microorganisms8040573] [Cited by in Crossref: 104] [Cited by in F6Publishing: 108] [Article Influence: 52.0] [Reference Citation Analysis]
111 Sookoian S, Pirola CJ. Liver tissue microbiota in nonalcoholic liver disease: a change in the paradigm of host-bacterial interactions. Hepatobiliary Surg Nutr 2021;10:337-49. [PMID: 34159161 DOI: 10.21037/hbsn-20-270] [Reference Citation Analysis]